Fintech PR
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation
Chengdu 23Mofang Bio-tech Company, a startup in Chengdu Tianfu Software Park, has recently published an academic paper on genome-wide association study of photic sneeze reflex in the Chinese population in the Scientific Reports journal under Nature.
23Mofang: Research method innovation
Genetic testing, a rising life science technology in recent years, has become a hot track of innovation and entrepreneurship. Chengdu 23Mofang Bio-tech Company is one of the top runners on the track. Due to the unremitting pursuit of the “Moore’s law” in genetic testing field that the price of direct-to-customer (DTC) genetic testing will be halved at intervals as a result of technology upgrade, more than 300,000 genetic samples of Chinese people have been brought to 23Mofang, making it top the list of Chinese DTC genetic testing companies with such a large database.
Genetic testing is closely related to biotechnology. 23Mofang has built a biological laboratory itself, which can conduct genetic testing for 400,000 people every year. It is also building a genetic testing laboratory ranking second largest in the world and first in Asia with an annual capacity of 4 million people. Furthermore, 23Mofang also works with some professional medical institutions to carry out research. The first academic paper of the company published in the Scientific Reports journal under Nature was a result of the collaboration with Mengqiao Wang, PhD, Assistant Professor at Sichuan University West China School of Public Health on photic sneeze reflex.
Photic sneeze reflex (PSR) is a phenotype that refers to sneezing in response to exposure to bright light. Through the genome-wide association study (GWAS) of a large number of samples from Chinese population, 23Mofang has for the first time proved the association between PSR and heredity, and verified that PSR is affected by multiple genes and it is not exclusive to certain races but is heritable in many different races.
With professional guidance from Dr. Wang on statistical modeling and data visualization and with application of scientific achievements, 23Mofang harnessed its advantages in data collection and analysis. Both sides worked together to overcome challenges, resulting in original scientific discoveries and paper publishing.
Dr. Wang said, “The U.S. DTC genetic companies such 23andMe have published many academic papers on genetics, physiology, and phenotypes, while Chinese DTC genetic testing companies are at the nascent stage, but with a bright future.”
Besides Sichuan University, 23Mofang reportedly cooperates with universities and research institutions such as Fudan University; Kunming Institute of Zoology, CAS; Army Medical University; Beijing Institute of Genomics, CAS; and University of Electronic Science and Technology of China, to mainly study the possible effects of genetics on physiology, economics, and social behaviors of the Chinese people.
Tianfu Software Park: Becoming a globally oriented technology R&D and innovation center
According to the overall situation of the Chinese scientific papers in 2017 reported by the Institute of Scientific and Technical Information of China, the 100 international papers with high influence in China in 2017 were published by 69 institutions, wherein, 80 were from colleges and universities, 14 were from research institutes, 5 were from hospitals affiliated to colleges and universities and other hospitals, and 1 was from a company. The inclusion of the company paper into the 100 papers with high influence shows that the influence of papers published in the name of companies in China is gaining influence. According to the statistics of Angang Technology, enterprises seldom published scientific papers in China 30 years ago, and the handful that published such papers were mostly state-owned heavy industry enterprises of some scale. Now, with new economy, private enterprises represented by 23Mofang are scrambling to publish international papers, the 3-decade shift from state-owned enterprises to private enterprises, from heavy industry to new economy, and from China to the world is truly remarkable.
The phenomenon of publishing papers in the name of enterprises is relatively rare. However, the research vitality of private enterprises in Chengdu is far more active than it seems, because enterprises are more inclined to apply for patents after obtaining some scientific achievements than publish papers. According to incomplete statistics, enterprises in Tianfu Software Park, one of the most active parks in terms of intellectual property activities, have applied for 22,000 patents (including PCTs) and possessed over 19,500 software copyrights, wherein, enterprises that possess more patents include TD Tech, DFINE, XGimi Technology, CK Science and Technology, Idealsee, Pinguo Technology, SKSpruce, and China Mobile IoT, etc., and enterprises with more copyrights include SuperMap Software, Jiaoda Guangmang, TD Tech, Aostar, ChinaWiserv Technologies, and Daqsoft, etc. And the above does not include holders of prolific patents and copyrights that have set up their R&D centers in Tianfu Software Park, such as IBM, Philips, Siemens, Ericsson, Dell, TCL, Alibaba, and Tencent.
The world-renowned R&D achievements of enterprises from Tianfu Software Park don’t come by accident. Adhering to a professional, platform-based and international development concept, Tianfu Software Park has been focusing on the frontier technology, combining new economy and traditional industries, and giving priority to the Belt and Road Initiative in recent years, and by serving as a platform and link, it has further integrated industrial resources to build the industrial ecology and promote industry innovation. Well-known domestic and overseas enterprises such as IBM, SAP, Alibaba, and Tencent have settled in the park. The “5Cs” Cultivation Program for entrepreneurship in Tianfu Software Park covers capital, talents, circles, markets, and entrepreneurship coaching, making it a successful incubator for some leading enterprises and brands such as Medlinker, XGimi, and Codoon.
The complete industry ecosystem furnishes sci-tech talents with a favorable environment to grow. Talents, whether junior level talents to mid to senior level talents, can all find a robust career development path in Tianfu Software Park, which creates a strong talent aggregation effect. A growing number of domestic enterprises are willing to set their national or even global R&D headquarters there; and in turn, more talents will be attracted to gather there, thus forming a virtuous circle. Industrial clusters in spheres of software product R&D, communication technology, IC design, mobile interconnection, digital entertainment, techfin, and shared service center, etc. have generally taken shape in the park, covering cloud computing, big data, artificial intelligence, Internet of Things, blockchain, and VR/AR, etc. The park, as a nationally-known innovation landmark, has now become an important destination for well-known domestic and foreign software and information service providers in their strategic layouts. Tianfu Software Park is becoming a globally oriented technology R&D and research innovation center.
SOURCE Chengdu Tianfu Software Park
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
-
Latest News6 days ago
Bitrue Gears Up for 2024 Bitcoin Halving with Trading Competition
-
Latest News6 days ago
Global Airlines Appoints New Head of Finance from KPMG
-
Latest News7 days ago
Former Dreambox CEO Jessie Woolley-Wilson Joins Owl Ventures as Operating Partner
-
Latest News4 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News6 days ago
Spendesk combines procurement with spend management through Okko acquisition
-
Latest News6 days ago
BtcTurk Organizes Half Marathon in Istanbul to Celebrate Halving Period
-
Latest News6 days ago
99Bitcoins Reveals Website Revamp and Expansion Plans With Incentivized Learning Through Tokenization